Medidata Solutions Inc to Post Q1 2018 Earnings of $0.17 Per Share, Dougherty & Co Forecasts (MDSO)
Medidata Solutions Inc (NASDAQ:MDSO) – Equities research analysts at Dougherty & Co issued their Q1 2018 earnings per share (EPS) estimates for shares of Medidata Solutions in a report issued on Monday. Dougherty & Co analyst G. Mannheimer forecasts that the company will post earnings per share of $0.17 for the quarter. Dougherty & Co currently has a “Buy” rating and a $75.00 target price on the stock.
Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Thursday, February 8th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.10. The firm had revenue of $141.20 million during the quarter, compared to analysts’ expectations of $140.65 million. Medidata Solutions had a net margin of 8.14% and a return on equity of 11.59%. The company’s revenue was up 13.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.33 earnings per share.
Shares of Medidata Solutions (NASDAQ:MDSO) opened at $63.57 on Tuesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.50 and a quick ratio of 3.37. The stock has a market cap of $3,661.76, a P/E ratio of 71.82, a price-to-earnings-growth ratio of 3.11 and a beta of 1.58. Medidata Solutions has a one year low of $54.36 and a one year high of $85.92.
Large investors have recently added to or reduced their stakes in the stock. Summit Creek Advisors LLC acquired a new position in Medidata Solutions during the 4th quarter valued at $5,137,000. AMP Capital Investors Ltd acquired a new position in Medidata Solutions during the 3rd quarter valued at $2,194,000. KAMES CAPITAL plc raised its stake in Medidata Solutions by 54.6% during the 4th quarter. KAMES CAPITAL plc now owns 25,521 shares of the company’s stock valued at $1,617,000 after purchasing an additional 9,012 shares during the last quarter. Zions Bancorporation acquired a new position in Medidata Solutions during the 3rd quarter valued at $256,000. Finally, Schwab Charles Investment Management Inc. raised its stake in Medidata Solutions by 38.3% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 326,950 shares of the company’s stock valued at $25,522,000 after purchasing an additional 90,572 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.
In related news, CFO Rouven Bergmann sold 2,000 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $65.40, for a total transaction of $130,800.00. Following the completion of the transaction, the chief financial officer now directly owns 91,775 shares in the company, valued at approximately $6,002,085. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Carlos Dominguez sold 9,066 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $66.85, for a total transaction of $606,062.10. Following the transaction, the director now owns 66,020 shares of the company’s stock, valued at $4,413,437. The disclosure for this sale can be found here. Insiders sold 24,010 shares of company stock valued at $1,630,556 over the last 90 days. 5.80% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Medidata Solutions Inc to Post Q1 2018 Earnings of $0.17 Per Share, Dougherty & Co Forecasts (MDSO)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/02/15/medidata-solutions-inc-to-post-q1-2018-earnings-of-0-17-per-share-dougherty-co-forecasts-mdso.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.